Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 3.00 — trading above book value
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- Loss-making — negative ROE of -4.3%
- Revenue growing at 15% annually
AtriCure, Inc. (ATRC) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $1.5 billion . Key value metrics: P/B ratio 3.00, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
AtriCure, Inc. — Fundamental Analysis Summary
On financial health, ATRC shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and negative return on equity of -4.3% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.13.
StockPik's composite Value Score for ATRC is 76/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ATRC reports a high gross margin of 75.0% (sector average: 33.5%) and a negative operating margin of -3.8%.
ATRC shows revenue growing at 15% year-over-year, with earnings growing at 74%.